Pharmacologic agents associated with QT interval prolongation.
Diverse classes of medications are associated with QT interval prolongation and expose patients to the risk of potentially fatal ventricular arrhythmias. Clinicians can minimize adverse events by avoiding prescription of multiple medications associated with QT interval prolongation in high-risk patients.
Olsen
Keith M
KM
University of Nebraska Medical Center, Omaha, NE, USA.
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects*; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D016757:Death, Sudden, Cardiac / Q000209:etiology; D024841:Fluoroquinolones / Q000009:adverse effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis; D018942:Macrolides / Q000009:adverse effects; D012307:Risk Factors; D016171:Torsades de Pointes / Q000139:chemically induced / Q000175:diagnosis
D000889:Anti-Arrhythmia Agents; D000900:Anti-Bacterial Agents; D000929:Antidepressive Agents, Tricyclic; D014150:Antipsychotic Agents; D024841:Fluoroquinolones; D018942:Macrolides